ReviewEndocrine2026
Anti-obesity drugs: comprehensive review and emerging therapies.
Review in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, an epidemic of modern world lifestyle, has a substantial negative impact on both health and the economy. Traditional weight management strategies, such as dietary modifications and lifestyle changes, are often inadequate for long-term weight control, warranting the immediate intervention of pharmaceutical assistance. This review article evaluates the status of presently approved anti-obesity medications like lipase inhibitors, incretin-based medicines, dual agonists, and melanocortin receptor agonists for their adverse events, alongside novel therapeutic candidates under clinical investigation. The article comprises the impacts of these medications on energy balance, appetite regulation, and metabolic health in the assessment of their mechanisms of action, efficacy, safety profiles and their therapeutic potential with respect to obesity phenotypes. This review article also sheds light on recent promising advancements in anti-obesity innovative therapies such as neuromedin U receptor agonists, amylin/calcitonin dual agonists, and a non-peptide oral GLP-1 receptor agonist. Key future research strategies and directions include the development of multi-targeted and combination therapies were also discussed.
Indexed as
Identifiers
41627597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.